MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5551/jat.64304

Медицинская библиотека · Journal of atherosclerosis and thrombosis · 2023

Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study.

Kamiya Kiwamu, Takei Makoto, Nagai Toshiyuki, Miyoshi Toru, Ito Hiroshi, Fukumoto Yoshihiro, Obara Hitoshi, Kakuma Tatsuyuki, Sakuma Ichiro, Daida Hiroyuki, Iimuro Satoshi, Shimokawa Hiroaki, Kimura Takeshi, Nagai Ryozo, Anzai Toshihisa

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

AIMS: We aimed to investigate the association between non-lipid residual risk factors and cardiovascular events in patients with stable coronary artery disease (CAD) who achieved low-density lipoprotein cholesterol (LDL-C) <100 mg/dL from the Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study.

METHODS

The REAL-CAD study was a prospective, multicenter, open-label trial. As a sub-study, we examined the prognostic impact of non-lipid residual risk factors, including blood pressure, glucose level, and renal function, in patients who achieved LDL-C <100 mg/dL at 6 months after pitavastatin therapy. Each risk factor was classified according to severity. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and unstable angina requiring emergency hospitalization.

RESULTS

Among 8,743 patients, the mean age was 68±8.2 years, and the mean LDL-C level was 84.4±18 mg/dL. After adjusting for the effects of confounders, an estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73 m2 showed the highest risk of the primary outcome (hazard ratio [HR] 1.92; 95% confidence interval [CI] 1.45-2.53). The combination of eGFR ≤ 60 and hemoglobin A1c (HbA1c) ≥ 6.0% also showed the highest risk of all-cause death (HR, 2.42; 95% CI, 1.72-3.41).

CONCLUSIONS

In patients with stable CAD treated with pitavastatin and who achieved guidelines-directed levels of LDL-C, eGFR and HbA1c were independently associated with adverse events, suggesting that renal function and glycemic control could be residual non-lipid therapeutic targets after statin therapy.

Для цитирования: Kamiya Kiwamu, Takei Makoto, Nagai Toshiyuki, Miyoshi Toru, Ito Hiroshi, Fukumoto Yoshihiro, Obara Hitoshi, Kakuma Tatsuyuki, Sakuma Ichiro, Daida Hiroyuki, Iimuro Satoshi, Shimokawa Hiroaki, Kimura Takeshi, Nagai Ryozo, Anzai Toshihisa. Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study.. Journal of atherosclerosis and thrombosis. 2023. DOI: 10.5551/jat.64304.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.